Featured Articles
-
The Use Of Injectable Packaging From Early Development To Commercialization
2/20/2024
While in their early-stage development of a mAb biosimilar for oncology treatment, a large biopharmaceuticals company sought a packaging recommendation: a stopper to maintain high-quality standards.
-
Vials Vs. Cryobags For Cryopreservation Of Therapeutically Relevant T Cells
7/20/2023
Explore how COP 50 mL vials could serve as a basis for cell therapies and storage solution to help facilitate the manufacture and commercialization of cell products.
-
Containment Solutions To Help Emerging Biologic Companies Get Products To The Market Faster
3/24/2023
Gain solutions on how to set up your small company for long-term success using packaging containment offerings and services to help mitigate risks and speed up your time to market.
-
A Risk-Based Approach To Injectable Combination Product Development
3/14/2023
Examine how to establish a holistic approach to drug-device combination product (DDCP) development and how to assess and manage risk throughout the development and approval process.
- West Expands Corning Collaboration And Launches First Product 2/8/2023
-
West Introduces Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System At BIO International Convention
6/13/2022
Daikyo Crystal Zenith® (CZ®) is a technologically advanced cyclic olefin polymer containment and delivery system that offers an alternative to glass, mitigating the risk of breakage and reducing the chance of particulates, contamination, and extractables.
-
Gene Therapy: Maintaining Sterility At Low Temperature Storage
A gene therapy for pediatric Spinal Muscular Atrophy required a leak and break-resistant container which maintains sterility over product shelf life, through freeze and defrost cycles.
-
De-Risking Visible Particles Through Component Selection
Explore a summary of the FDA’s recent draft guidance “Inspection of Injectable Products for Visible Particulates” and how it applies to components.
-
Delivering Market Success For Pharma Partners From Concept To Patient
The development of drug delivery devices that are innovative, intuitive, patient friendly, and patient safe must address certain areas of concern that are particular to both biologic and biosimilar therapies.
-
Is It Ever Too Soon To Start Your Extractables And Leachables Assessment?
Learn what you need to know about planning for your extractables and leachables testing programs to mitigate delays to your drug development timelines.